Add Formweb to your mobile device
Approved Formulary
Search results for:
fluvoxaMINE
fluvoxaMINE
Brand names: Luvox
| Form | Strength |
|---|---|
| TABLET, ORAL | 50 mg |
Display Selective-serotonin Reuptake Inhibitors Class:
28160420
Medication comments:
| 2023 American Geriatrics Society Beers Criteria® for potentially inappropriate medication use in older adults. | |
|---|---|
| Medication: | fluvoxaMINE (Luvox) |
| Criteria 2: Potentially inappropriate medication use in older adults due to drug–disease or drug–syndrome interactions that may exacerbate the disease or syndrome. (Table 3) | |
| Drug(s) ⇆ disease or syndrome | antidepressants (selected classes: SSRIs) ⇄ History of falls or fractures |
| Rationale | May cause ataxia, impaired psychomotor function, syncope, or additional falls. Antidepressants (selected classes): evidence for risk of falls and fractures is mixed; newer evidence suggests that SNRIs may increase falls risk. If one of the drugs must be used, consider reducing the use of other CNS-active medications that increase the risk of falls and fractures. (i.e., anticholinergics, selected antidepressants, antiepileptics, antipsychotics, sedative/hypnotics including benzodiazepines and, Nonbenzodiazepine benzodiazepine receptor agonist hypnotics, opioids) and implement other strategies to reduce fall risk. |
| Recommendation | Avoid unless safer alternatives are not available. |
| Quality of evidence: Moderate, Strength of Recommendation: Strong | |
| Criteria 3: Potentially inappropriate medications: drugs to be used with caution in older adults. (Table 4) | |
| Drug(s) | antidepressants (selected: SSRIs) |
| Rationale | May exacerbate or cause SIADH or hyponatremia; monitor sodium levels closely when starting or changing dosages in older adults. |
| Recommendation | Use with caution |
| Quality of evidence: Moderate, Strength of Recommendation: Strong | |
| Criteria 4: Potentially clinically important drug-drug interactions that should be avoided in older adults. (Table 5) | |
| Interacting drug(s) or class(es) | antidepressants (TCAs, SSRIs, and SNRIs) ⇄ CNS-active agents |
| Risk Rationale | Increased risk of falls and of fracture with the concurrent use of ≥3 CNS-active agents (antiepileptics including gabapentinoids, antidepressants, antipsychotics, benzodiazepines, Nonbenzodiazepine benzodiazepine receptor agonist hypnotics, opioids, and skeletal muscle relaxants). |
| Recommendation | Avoid concurrent use of ≥3 CNS-active drugs Click for list; minimize the number of CNS-active drugs. |
| Quality of evidence: High, Strength of Recommendation: Strong | |
Last updated: Sep. 25, 2025
- Black Box Warnings Suicidal Ideation
- Look-Alike/Sound-Alike fluvoxaMINE confused with flavoxATE, fluPHENAZine